Pramipexole in patients with early Parkinson's disease (PROUD): A randomised delayed-start trial

The Lancet Neurology

Volumn 12, Issue 8, 2013, Pages 747-755

  Schapira, Anthony HV ^a   McDermott, Michael P ^b   Barone, Paolo ^c   Comella, Cynthia L ^d   Albrecht, Stefan ^e   Hsu, Helen H ^f   Massey, Daniel H ^g   Mizuno, Yoshikuni ^h   Poewe, Werner ⁱ   Rascol, Olivier ^j   Marek, Kenneth ^k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF SALERNO   (Italy)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g BOEHRINGER INGELHEIM LTD   (United Kingdom)

^h KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j TOULOUSE UNIVERSITY HOSPITAL   (France)

^k INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAMIPEXOLE;

ADULT; ARTICLE; BACKACHE; BECK DEPRESSION INVENTORY; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HALLUCINATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROIMAGING; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84880329276     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70117-0     Document Type: Article

References (29)

1. Olanow CW, Kieburtz K, Schapira AH Why have we failed to achieve neuroprotection in Parkinson's disease?. Ann Neurol 2008, 64(suppl 2):S101-S110.
2. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009, 24:647-654.
3. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011, 26(suppl 3):S2-41.
4. Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004, 91:1075-1081.
5. Iravani MM, Sadeghian M, Leung CC, et al. Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. Exp Neurol 2008, 212:522-531.
6. Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006, 96:1315-1321.
7. Schapira AH, Albrecht S, Barone P, et al. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord 2010, 25:1627-1632.
8. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001, 57:2089-2094.
9. Hoehn MM, Yahr MD Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
10. Early clinical drug evaluation unit (ECDEU). Clinical global impressions. ECDEU assessment manual for psychopharmacology 1976, 216-222. National Institute of Mental Health (NIMH), NIMH USA, Rockville, MD. revised edition. W. Guy (Ed.).
11. Grant JE, Levine L, Kim D, Potenza MN Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 2005, 162:2184-2188.
12. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278. ADAGIO Study Investigators.
13. Molenberghs G What to do with missing data?. J R Stat Soc Series A (Statistics in Society) 2007, 170:861-863.
14. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995, 18:338-347.
15. Shannon KM, Bennett JP, Freidman JH Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997, 47:724-728.
16. Schapira AH, Obeso J Timing of treatment initiation in Parkinson's disease: a need for reappraisal?. Ann Neurol 2006, 59:559-562.
17. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993, 328:176-183. Parkinson Study Group.
18. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
19. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008, 23:2194-2201.
20. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011, 10:415-423.
21. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004, 61:561-566. Parkinson Study Group.
22. Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009, 24:564-573.
23. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000, 284:1931-1938. Parkinson Study Group.
24. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661. Parkinson Study Group.
25. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003, 54:93-101.
26. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson's disease. Neurology 2007, 69:1480-1490. The Parkinson Study Group PRECEPT Investigators.
27. Olanow CW, Kieburtz K Defining disease-modifying therapies for PD-a road map for moving forward. Mov Disord 2010, 25:1774-1779.
28. Yacoubian TA, Standaert DG Targets for neuroprotection in Parkinson's disease. Biochim Biophys Acta 2009, 1792:676-687.
29. Schapira AH, Gegg ME Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci USA 2013, 110:3214-3215.